Accession PRJCA024694
Title TopDouble-IA1
Relevance BTC
Data types Monitoring biomarker
Organisms Homo sapiens
Description A Phase IIIb, Single Arm, Open-label, Multi-center Study on Durvalumab in Combination with Gemcitabine-based Chemotherapy as First Line Treatment for Chinese Patients with unresectable Biliary Tract Cancers (TopDouble)
Sample scope Multiisolate
Release date 2024-03-26
Grants
Agency program Grant ID Grant title
AstraZeneca Investment (China) Co., Ltd. D933AL00006
Submitter huichuan Sun (sun.huichuan@zs-hospital.sh.cn)
Organization Zhongshan Hospital, Fudan University
Submission date 2024-03-26

Project Data

Resource name Description